Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

20145,329 citationsJournal Articlebronze Open Access

Authors

Shannon L. Maude · University of Pennsylvania

Noelle V. Frey · University of Pennsylvania

Pamela A. Shaw · University of Pennsylvania

Richard Aplenc · Children's Hospital of Philadelphia

David M. Barrett · University of Pennsylvania

Nancy Bunin · Children's Hospital of Philadelphia

Anne Chew

Abstract

Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed. (Funded by Novartis and others; CART19 ClinicalTrials.gov numbers, NCT01626495 and NCT01029366.).

Topics & Keywords

CAR-T cell therapy research Virus-based gene therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 371, Issue 16, pp. 1507-1517

DOI: 10.1056/nejmoa1407222

Field-Weighted Citation Impact: 180.87